Scaling AAV manufacturing: upstream strategies to cut COGs and accelerate commercial readiness

The gene therapy landscape is expanding rapidly, but manufacturing costs remain the primary barrier to commercial and clinical accessibility. Therapy developers must rethink upstream strategy to reduce cost per dose without compromising quality. Early‑stage companies and emerging developers often struggle to scale beyond research formats, while CDMOs face pressure to expand capacity, increase flexibility, and accelerate tech transfer.

This webinar explores data‑driven, scalable, upstream solutions for transient AAV production, integrating insights from the iCELLis™ fixed‑bed platform, scalable Xcellerex™ X‑platform stirred‑tank bioreactors, and enhanced transient transfection workflows.

What you will learn:
• Strategies to reduce COGs by adopting scalable upstream technologies and improving transient transfection efficiency
• How to optimize V/A ratios and P/V strategies to enhance AAV production performance
• Practical insights for biotech companies, therapeutic developers, and CDMOs to scale AAV manufacturing and prepare for commercial readiness

Learn more about our integrated viral vector solutions: https://info.cytivalifesciences.com/aav-workflow.html